Yazen Raises €50M Series B Led by Verdane for Digital Obesity Care

Yazen, a Swedish digital healthcare provider specializing in the medical treatment of obesity as a chronic disease, has raised a €50 million Series B round. Verdane led the financing, which was announced on October 8, 2026.

What Yazen Does

Yazen's care model combines modern weight-loss medication with continuous digital support from a multidisciplinary team of doctors, dietitians, psychologists, and physiotherapists. A company study reports that 70% of patients remain in treatment after 12 months.

Headquartered in Sweden, Yazen operates across eight European countries: Sweden, Norway, Denmark, the Netherlands, the UK, Germany, Switzerland, and Spain. The company reports more than 50,000 patients actively in treatment and a team of 290 staff, including 115 licensed doctors.

The Round

Round type: Series B
Amount raised: €50,000,000 EUR
Announced: October 8, 2026
Lead investor: Verdane

Investor Group

The Series B included participation from:

Verdane (lead)
Evli Growth Partners

Why It Matters

Yazen addresses obesity as a chronic disease rather than a short-term condition, pairing weight-loss medication with ongoing digital care from a multidisciplinary clinical team. The reported 70% 12-month retention rate speaks to the engagement model, while the company's footprint across eight European markets and more than 50,000 active patients demonstrate meaningful scale in digital obesity care.

The €50 million Series B, led by Verdane with participation from Evli Growth Partners, provides capital to support Yazen's continued growth in European digital healthcare.

Acquisition Context

Digital healthcare platforms with clinical depth, cross-border operations, and demonstrated patient retention are increasingly attractive assets. Yazen's combination of licensed medical staffing, a multidisciplinary care model, and multi-country reach positions it as a notable player in the European obesity treatment market. Companies tracking digital health and chronic care assets will want to follow how Yazen deploys this Series B.